| Literature DB >> 34858098 |
Eleni Giannopoulos1, Michelle Snow2, Mollie Manley3, Katie McEwan4, Andrew Stechkevich5, Meredith Elana Giuliani6, Janet Papadakos7.
Abstract
BACKGROUND: The objective of this study was to determine if search request forms, which are used when a patron's request for information cannot be fulfilled at the time of contact with the library team, can be used to identify gaps in consumer health library collections. CASEEntities:
Keywords: collection development; consumer health; gap analysis; neoplasm
Mesh:
Year: 2021 PMID: 34858098 PMCID: PMC8608165 DOI: 10.5195/jmla.2021.895
Source DB: PubMed Journal: J Med Libr Assoc ISSN: 1536-5050
Search request form requester information (n=249)
|
|
| |
| Patron | Patient | 132 (62.9%) |
| Family member | 56 (22.5%) | |
| Other (e.g., staff, friend, visitor) | 23 (9.2%) | |
| Unspecified | 38 (15.3%) | |
|
| ||
| Cancer type | Breast | 58 (23.3%) |
| Hematology | 41 (16.5%) | |
| Gynecology | 25 (10.0%) | |
| Gastrointestinal | 23 (9.2%) | |
| Genitourinary | 22 (8.8%) | |
| Sarcoma | 21 (8.4%) | |
| Head and neck | 15 (6.0%) | |
| Unspecified | 12 (4.8%) | |
| Lung | 11 (4.4%) | |
| Other (e.g., neuroendocrine cancer) | 9 (3.6%) | |
| Melanoma | 7 (2.8%) | |
| Brain | 5 (2.0%) | |
|
| ||
| Method of delivery | 173 (69.5%) | |
| Pick-up | 61 (27.7%) | |
| 19 (9.2%) | ||
| Unspecified | 10 (4.0%) | |
| Type of request | ||
| Multiple requests for information | 162 (65.1%) | |
| Single request for information | 87 (34.9%) | |
Some respondents selected more than one option
Figure 1Resources provided to library patrons.
Content gaps identified in search requests
| Content gap categories | Content gap subcategories | Frequency | Reasons for gaps | |||
|---|---|---|---|---|---|---|
|
|
|
|
| |||
|
| ||||||
|
| Rare cancer diagnosis | 25 | X | |||
| Pathology (e.g., growth, morphology) | 2 | X | X | |||
| Environmental risks (e.g., radiation exposure) | 5 | X | X | |||
|
| Visual inspection with acetic acid for cervical cancer | 1 | X | X | ||
| Gadolinium-based contrast agents for MRI | 2 | X | X | |||
|
| ||||||
|
| Integrated boost radiation | 1 | X | |||
| Targeted intraoperative therapy | 1 | X | ||||
| Metabolically adaptive radiation | 1 | X | ||||
|
| Reconstructive surgery (e.g., breast and cervical cancer) | 6 | X | |||
| Amputation (e.g., preventing sarcoma metastasis) | 1 | X | ||||
|
| Dental issues (e.g., tooth sensitivity) | 1 | X | |||
| Vision loss | 1 | X | ||||
| Gynecologic problems (e.g., vaginal discharge) | 1 | X | ||||
| Axillary web syndrome | 1 | X | ||||
|
| Tamoxifen vs. aromatase inhibitors (e.g., Letrozole) | 4 | X | |||
| Tamoxifen vs. radiotherapy | 1 | X | ||||
| Lumpectomy vs. mastectomy | 3 | X | ||||
| Breast reconstructive surgery; saline vs. silicone | 5 | X | ||||
| Cyclophosphamide vs. docetaxel chemotherapy | 1 | X | ||||
| Hormonal therapy vs. radiotherapy | 1 | X | ||||
|
| Radical hysterectomy vs. fertility-saving treatment | 2 | X | |||
| Surgery vs. chemotherapy | 1 | X | ||||
|
| Lobectomy vs. segmentectomy or pneumonectomy | 1 | X | |||
|
| Temodar/radiation vs. PCV/radiation | 1 | X | |||
|
| Partial vs. radical nephrectomy | 1 | X | |||
|
| Drug manufacturers | 1 | X | |||
|
| ||||||
|
| Chances and signs of recurrence | 5 | X | |||
| Age-related survival | 3 | X | ||||
| Treatment-related survival and quality-of-life | 8 | X | ||||
| Risk of developing secondary conditions (e.g., diabetes due to prednisone) | 1 | X | ||||
|
| Chances of metastasis | 8 | X | |||
| Secondary cancers | 3 | X | ||||
|
| ||||||
|
| Support groups (e.g., locations, types of groups) | 5 | X | |||
| Podcasts | 1 | X | ||||
| Inpatient programs | 1 | X | ||||
|
| Memory improvement strategies | 1 | X | |||
|
| ||||||
|
| Anti-angiogenesis (e.g., turmeric, flax) | 1 | X | X | ||
|
| Ganoderma (i.e., fungal medicine) | 1 | X | X | ||
| Cannabis (e.g., pancreatic cancer) | 6 | X | X | |||
| Red reishi mushroom | 1 | X | X | |||
| Vitamin C | 2 | X | X | |||
| Thermal therapy | 1 | X | X | |||
| Mistletoe treatment | 2 | X | X | |||
| Oxygen therapy | 1 | X | X | |||
|
| ||||||
|
| Paclitaxel | 1 | X | |||
| Capecitabine | 2 | X | ||||
| Doxorubicin | 1 | X | ||||
| Aromatase inhibitors | 1 | X | ||||
| Cyclophosphamide | 1 | X | ||||
| Docetaxel | 1 | X | ||||
|
| Stivarga | 1 | X | |||
| Arimidex | 1 | X | ||||
| Letrozole | 1 | X | ||||
| Tamoxifen | 1 | X | ||||
|
| Revlimid | 1 | X | |||
|
| Auxiliary lymph node dissection | 2 | X | |||
|
| Prostatectomy | 1 | X | |||
|
| Exposure (e.g., breast cancer) | 1 | X | |||
| Health risks (e.g., prostate cancer) | 1 | X | ||||
|
| Cannabis | 2 | X | |||
|
| Myelodysplastic syndrome and myelofibrosis (polycythemia vera) | 2 | X | |||
| Malignant mixed Mullerian tumor | 1 | X | ||||
| Leiomyosarcoma | 1 | X | ||||
| Adenocarcinoma | 1 | X | ||||
| Stomach cancer (e.g., H. pylori) | 1 | X | ||||
| Ovarian cancer | 1 | X | ||||
| Anal dysplasia disease | 1 | X | ||||
| Anaplastic astrocytoma (e.g., hormone effects) | 1 | X | ||||